Delivery Order SPE2DB20D2104-SPE2DB23FR20R
- Not listed
- This federal contract award to AmerisourceBergen Drug Corp is a delivery order valued at $2,501.97 for the supply of Lantus SoloStar 100 unit/mL 3mL insulin pens. The contract is held under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC enables AmerisourceBergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide Lantus SoloStar 100 unit/mL 3mL insulin pens. The firm-fixed-price delivery order, valued at $2,099.80, has an ultimate completion date of December 21, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
- This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. The contract is a delivery order valued at $2,110.95 with a period of performance through September 27, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued up to $999,999,999, for the...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract worth $2,958.74 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of Lantus SoloStar 100 unit/mL 3mL insulin pens. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle...
- This federal contract award, valued at $1,068.84, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, for the supply of Lantus SoloSTAR 100 unit/ml 3ml insulin pens. The contract is a delivery order, with a firm fixed price pricing type, and an ultimate completion date of June 3, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Lantus SoloStar insulin pens. The contract has a total ceiling value of $1,022.80 and runs through February 27, 2025. It is a firm fixed-price contract, with no set-aside designation noted. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract worth $1,943.76 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to AmerisourceBergen Drug Corp, with a potential value of up to $999,999,999.00 and a performance period through December 31, 2025. The...
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The contract, valued at $1,187.60, is for the delivery of Lantus SoloStar 100 unit/mL 3mL insulin pens. This order does not have a set-aside designation. AmerisourceBergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00 and effective through December 31,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 unit/mL 3 mL insulin pens. The contract has a ceiling value of $1,187.60 and is a firm fixed price delivery order with a completion date of May 17, 2024. AmerisourceBergen, a major pharmaceutical distribution company, has a large Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999.00 through December 31,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The contract is for the provision of Lantus SoloStar 100 Unit/mL 3mL insulin pens, a branded medication, with a firm fixed price of $1,748.36 and a completion date of February 28, 2024. The contract is a delivery order, which is part of a larger indefinite delivery contract (IDC) awarded solely to...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB23FR20RDelivery Order
This federal contract award is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. The contract has a firm fixed price of $1,824.42 and a period of performance through November 25, 2022. This contract is not designated as a set-aside requirement. The award is associated with AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for AmerisourceBergen to provide a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, and other critical medical commodities, to support military healthcare programs globally. AmerisourceBergen's parent company is Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 11/23/22 |